MedTrace Logo

Helicobacter Pylori Eradication in Functional Dyspepsia

NCT04697641 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2021-01-14

No results posted yet for this study

Summary

This study is designed to study benefit of eradicating Helicobacter Pylori in patients with functional dyspepsia as compared to symptomatic treatment only. Helicobacter pylori positive patients with Functional Dyspepsia will be divided into two study groups, one will receive Helicobacter pylori eradication therapy and other will receive symptomatic treatment. Symptom relief based on Likert scale will be compared in both groups.

Conditions

  • Dyspepsia
  • Helicobacter Pylori Infection

Interventions

DRUG

Clarithromycin 500mg

Clarithromycin 500 mg twice a day for two weeks

DRUG

Amoxicillin 1000 MG

Amoxicillin 1000mg twice a day for two weeks

DRUG

Pantoprazole 40mg

Pantoprazole 40 mg or equivalent for eight weeks

DRUG

Levosulpiride

Levosulpiride 25 mg as and when required before meals

DRUG

Acotiamide

Acotiamide 100mg as when required before meals

DRUG

Itopride

Itopride 50mg as when required before meals

Sponsors & Collaborators

  • Sir Ganga Ram Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2019-05-31
Completion
2019-05-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04697641 on ClinicalTrials.gov